National Bank Financial Equities Analysts Increase Earnings Estimates for Wheaton Precious Metals Corp (WPM)

Wheaton Precious Metals Corp (TSE:WPM) – Equities researchers at National Bank Financial lifted their FY2018 EPS estimates for Wheaton Precious Metals in a research note issued to investors on Wednesday, November 14th. National Bank Financial analyst S. Nagle now anticipates that the company will post earnings of $0.65 per share for the year, up from their prior forecast of $0.62. National Bank Financial also issued estimates for Wheaton Precious Metals’ Q4 2018 earnings at $0.12 EPS, FY2019 earnings at $0.54 EPS and FY2020 earnings at $0.69 EPS.

Equities Analysts Set Expectations for Loblaw Companies Ltd’s FY2018 Earnings (L)

Loblaw Companies Ltd (TSE:L) – Equities researchers at Desjardins raised their FY2018 earnings estimates for shares of Loblaw Companies in a note issued to investors on Thursday, November 15th. Desjardins analyst K. Howlett now anticipates that the company will post earnings of $4.55 per share for the year, up from their prior estimate of $4.38. Desjardins currently has a “Buy” rating and a $66.00 price target on the stock. Desjardins also issued estimates for Loblaw Companies’ Q4 2018 earnings at $1.01 EPS and FY2019 earnings at $4.19 EPS.

Oppenheimer Equities Analysts Decrease Earnings Estimates for Emerson Electric Co. (NYSE:EMR)

Emerson Electric Co. (NYSE:EMR) – Equities research analysts at Oppenheimer reduced their FY2019 earnings per share estimates for shares of Emerson Electric in a report issued on Tuesday, November 6th, according to Zacks Investment Research. Oppenheimer analyst C. Glynn now forecasts that the industrial products company will post earnings of $3.65 per share for the year, down from their previous estimate of $3.75.

Equities Analysts Issue Forecasts for Arcus Biosciences Inc’s FY2018 Earnings (RCUS)

Arcus Biosciences Inc (NYSE:RCUS) – Analysts at Wedbush increased their FY2018 earnings per share estimates for Arcus Biosciences in a research report issued on Tuesday, November 13th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($2.37) for the year, up from their prior forecast of ($2.53). Wedbush currently has a “Outperform” rating and a $22.00 target price on the stock. Wedbush also issued estimates for Arcus Biosciences’ Q1 2019 earnings at ($0.45) EPS, Q2 2019 earnings at ($0.47) EPS, Q3 2019 earnings at ($0.49) EPS, Q4 2019 earnings at ($0.51) EPS, FY2019 earnings at ($1.93) EPS, FY2020 earnings at ($2.15) EPS, FY2021 earnings at ($2.35) EPS and FY2022 earnings at ($1.95) EPS.

Equities Analysts Issue Forecasts for Trillium Therapeutics Inc’s Q3 2018 Earnings (TRIL)

Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) – Equities research analysts at Leerink Swann upped their Q3 2018 earnings per share (EPS) estimates for shares of Trillium Therapeutics in a report released on Wednesday, November 14th. Leerink Swann analyst J. Chang now expects that the biotechnology company will post earnings of ($0.69) per share for the quarter, up from their prior forecast of ($0.78). Leerink Swann also issued estimates for Trillium Therapeutics’ Q4 2018 earnings at ($0.78) EPS, FY2018 earnings at ($2.42) EPS and FY2019 earnings at ($1.34) EPS.

error: Content is protected !!